The story of Moonshot4Kids meets the White House Moonshot: CAC2 Member Janet Demeter (Jack’s Angels) encourages medical research investment into cures for children with cancer at the 2022 Cancer Moonshot announcement event. CAC2 Member, the National Brain Tumor Society (NBTS) launched a new research initiative, the DNA Damage Response Consortium, in partnership with Yale Cancer Center. The consortium will bring together a diverse team of renowned adult and pediatric researchers to rapidly advance a new class of promising potential treatments that can target a brain tumor’s DNA damage response network. More than 60% of patients with relapsed or refractory B-cell acute lymphoblastic leukemia achieved initial complete remission after receiving an investigational chimeric antigen receptor T-cell therapy, phase 1/phase 2 study results showed. The COVID-19 pandemic has greatly impacted pediatric oncology care, resulting in major staffing issues as well as physical, mental and financial pressure on those who care for children with cancer. But health care providers still managed to provide quality care to pediatric cancer patients, according to results published in American Cancer Society’s journal Cancer. Adolescent and young adult patients with central nervous system tumors who lived farther from the reporting hospital had a lower risk for death than those who lived closer, according to study results published in Journal of Neuro-Oncology. The reason, researchers wrote, could be that patients traveling from farther away receive treatment at higher-volume facilities with more experience treating CNS tumors. Blocking a protein chain reaction makes childhood leukemia cells more sensitive to an existing targeted treatment, a new study shows.